Clinical trials: Controlled Diabetes
Physical Inactivity, Type2 Diabetes Mellitus
Behavioral Change Communication for Physical Activity Among Females With Type2 Diabetes Mellitus
The marked discrepancy between predicted and actual prevalence of Type2 diabetes Mellitus (DM) with the actual cases rising earlier than expected, underscore the continuing relevance of tailored awareness and management…
- Trial name
- RCT (NCT00690326)
- Testing
- Behavioral change communication model(BCC) to promote physical activity, pamphlet-The printed pamphlet,'Physical activity:To control blood sugar/ Diabetes Mellitus'
- Where
- India
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Thiruvananthapuram Medical College
Insulin Resistance, Diabetes Mellitus
A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers
The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers.
- Trial name
- NCT00741026
- Testing
- Olanzapine 10 mg po qhs for 3 days
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
- Trial name
- NCT00286455
- Testing
- Alogliptin
- Where
- 67 sites in United States, Argentina and 16 more
- Volunteers
- 329 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Follow-Up Study for Exubera
In studies of Exubera in persons with diabetes, lung cancer occurred in a few more people who were taking Exubera than in people who were taking other diabetes medicines.
- Trial name
- FUSE (NCT00734591)
- Testing
- Exubera, Randomized diabetes therapy
- Where
- 321 sites in United States, Argentina and 23 more
- Volunteers
- 7,439 people
- Sponsor
- Pfizer
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as…
- Trial name
- NCT01515657
- Testing
- PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- PLx Pharma
Type 2 Diabetes Mellitus
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in…
- Trial name
- NCT00789750
- Testing
- Colesevelam, Pioglitazone
- Where
- 141 sites in United States
- Volunteers
- 562 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery
The purpose of this pilot study is to test the safety and feasibility of using two or three research modules in conjunction with an automated insulin delivery device (AID).
- Trial name
- NCT04784637
- Testing
- Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Virginia
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose…
- Trial name
- DUALTM IX (NCT02773368)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 88 sites in United States, Argentina and 9 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Peripheral Arterial Disease, Diabetic Foot
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of intramuscular administration of human placenta-derived cells (PDA-002) in subjects with…
- Trial name
- DFU-002 (NCT02264288)
- Testing
- PDA-002
- Where
- 45 sites in United States
- Volunteers
- 159 people
- Sponsor
- Celularity Incorporated
Diabetes, Depression
Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.
This proposed study will test the following hypothesis: Treating depression in Hispanics and African Americans with diabetes will improve their HbA1c and quality of life while on intervention and six months after intervention.
- Trial name
- NCT00624013
- Testing
- sertraline
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetes Mellitus, Type 2
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
- Trial name
- NCT03005288
- Testing
- BYM338 10 mg/kg
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in Hepatic Glucose Production (HGP) following institution of canagliflozin therapy and produce an additive or even…
- Trial name
- NCT02324842
- Testing
- Canagliflozin, Liraglutide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Treated With Insulin
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting.
- Trial name
- NCT05238142
- Testing
- MiniMed™ 780G Insulin Pump system
- Where
- 31 sites in United States
- Volunteers
- 574 people
- Sponsor
- Medtronic MiniMed, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.